Trevi Therapeutics (TRVI) Preferred Dividend Payments (2018 - 2019)
Trevi Therapeutics' (TRVI) quarterly Preferred Dividend Payments came in at $686000.0 in Q2 2019, down 46.95% year-on-year from $1.3 million in Q2 2018, and down 55.83% quarter-over-quarter from $1.6 million in Q1 2019.
Trevi Therapeutics (TRVI) Preferred Dividend Payments (2018 - 2019) Analysis & Trends
Trevi Therapeutics' Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at $686000.0 for Q2 2019.
- On a quarterly basis, Preferred Dividend Payments fell 46.95% year-over-year to $686000.0 in Q2 2019; TTM through Dec 2019 was $2.2 million, a 171.97% increase from a year earlier, with the FY2019 full-year figure at $2.2 million, up 705.14% from the prior year.
- Preferred Dividend Payments declined to $686000.0 in Q2 2019 per TRVI's latest filing, from $1.6 million in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $1.6 million in Q1 2019 and bottomed at -$4.3 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Trevi Therapeutics | 2.54 Bn | 2.54 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 686,000.00 |
| Mar 31, 2019 | 1.55 Mn |
| Dec 31, 2018 | -4.31 Mn |
| Sep 30, 2018 | 96,000.00 |
| Jun 30, 2018 | 1.29 Mn |
| Mar 31, 2018 | -195,000.00 |